Fund raise

MotifBio logo

Northland Capital Partners has acted as co-lead manager in a £20,000,000 fund raise for Motif Bio (MTFB.L). The funds raised will be used to complete the REVIVE-2 Phase 3 clinical trial and file a New Drug Application and Marketing Authorisation Application in H218 to achieve marketing approval of iclaprim in the US and Europe.